|
|
Antibody-Catch technology platform - GRS-044/15
| Third-party funded project |
| Project title |
Antibody-Catch technology platform - GRS-044/15 |
| Principal Investigator(s) |
Ernst, Beat
|
| Co-Investigator(s) |
Herrendorff, Ruben
|
| Organisation / Research unit |
Departement Pharmazeutische Wissenschaften / Molekulare Pharmazie (Ernst) |
| Project start |
01.03.2016 |
| Probable end |
01.03.2018 |
| Status |
Completed |
| Abstract |
| The goal of this project is to establish and validate a drug discovery platform, potentially enabling promising new personalized therapies in antibody-mediated autoimmune conditions. Platform-derived drugs are glycopolymers which selectively eliminate pathogenic autoantibodies in vivo. The new therapeutic concept with glycopolymers will be tested in autoimmune neuropathies, particularly in anti-MAG neuropathy, multifocal motor neuropathy, and Guillain-Barré syndrome. |
|
| Keywords |
Autoimmune neuropathies, autoantibodies, glycopolymers |
| Financed by |
Foundations and Associations
|
| |
|
|
MCSS v5.8 PRO. 0.481 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
23/01/2021
Research Database / FORSCHUNGSDATENBANK
|
